Concepedia

Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections

Aberra Fura, Ashish K. Khanna, Viral Vyas, Barry Koplowitz, Shu‐Ying Chang, Christian Caporuscio, David W. Boulton, Lisa J. Christopher, Kristina D. Chadwick, Lawrence G. Hamann,

Drug Metabolism and Disposition · 2009 · 99 citations · 10 references

DOI

Concepts

References

10

Discovery and Preclinical Profile of Saxagliptin (BMS-477118):  A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

David J. Augeri, Jeffrey A. Robl, David A. Betebenner et al. · Journal of Medicinal Chemistry · 2005 · 621 citations · Full text

, , +10

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses

Gary Herman, C. Melinda Stevens, Koen Vandyck et al. · Clinical Pharmacology & Therapeutics · 2005 · 519 citations

, , +14

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

Itamar Raz, Yu Chen, Mei Wu et al. · Current Medical Research and Opinion · 2008 · 262 citations

, , +16

Glucose‐lowering activity of the dipeptidyl peptidase‐4 inhibitor saxagliptin in drug‐naive patients with type 2 diabetes*

Julio Rosenstock, Serap Sankoh, James F. List · Diabetes Obesity and Metabolism · 2008 · 236 citations

, , +17

Interspecies correlation of plasma concentration history of methotrexate (NSC-740).

Robert L. Dedrick, Kenneth B. Bischoff, Daniel S. Zaharko · PubMed · 1970 · 185 citations

, , +7